trending Market Intelligence /marketintelligence/en/news-insights/trending/is7v9XfD6ns0SgUUcin_HQ2 content esgSubNav
In This List

Aeterna Zentaris initiates strategic review

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


Aeterna Zentaris initiates strategic review

Aeterna Zentaris Inc. formed a special board committee to review strategic options.

The review process may result in different outcomes or no outcome, the company noted. In addition, there is no guarantee that the company will pursue or execute transactions.

Macrilen, or macimorelin, is the company's medicine approved for diagnosing adult growth hormone deficiency in the EU and U.S. Adult growth hormone deficiency, or AGHD, occurs when the body's anterior pituitary gland does not produce enough growth hormone.

Summerville, S.C.-based Aeterna Zentaris is engaged in developing pharmaceutical products that address unmet medical needs of patients with rare endocrine diseases.

Torreya is acting as the company's financial adviser in the strategic review.